News

Compounded semaglutide, ubiquitous online, has certainly stepped into the void to make this therapy more accessible to the general public. But in the process, ...
Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.
The semaglutide group achieved a weight loss of 10.5% at 72 weeks compared with 2% for adults receiving placebo (estimated difference, –8.5 percentage points; 95% CI, –9.6 to –7.4; P < .001).
Compounded semaglutide, the active ingredient in Ozempic and Wegovy, is a version of the drug that has been mixed with other medications or ingredients. More From Newsweek Vault: ...
Semaglutide is growing in popularity thanks to social media buzz, but the phenomenon is backed by real stories: many people report significant weight loss with these injectable medicines.
A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.
The Brief. After May 22, compounding pharmacies can no longer make and sell semaglutide injections. They were initially allowed to because the FDA declared a shortage, but that period has ended.
In a subgroup analysis of based on different semaglutide medications, there was an increased risk for NAION in patients who received stand-alone Ozempic (semaglutide, Novo Nordisk) (HR = 6.27; 95% ...
More on off-label semaglutide uses: Ozempic Could Be Used to Treat Alcohol and Drug Addiction, Study Finds. Share This Article. Image by PhotoAlto/Odilon Dimier/Getty Images. Read This Next.
Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.
Share on Pinterest Ozempic, the active ingredient of which is semaglutide, can also reduce the risk of heart disease, according to research. Steve Christo – Corbis/Corbis via Getty Images ...
The average changes with semaglutide and liraglutide were -5.1% and -2.2%, respectively. In patients receiving T2D medication, the mean change was -3.2% as compared to -5.9% of those who were ...